News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Shankar Siva: OMET trial in oligometastatic HNSCC
Shankar Siva/iconcancercentre.com.au
Mar 28, 2025, 14:03

Shankar Siva: OMET trial in oligometastatic HNSCC

Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X:

“OMET trial (GORTEC 2014-04) in oligometastatic HNSCC.

N=69, SABR alone vs SABR + chemo + cetuximab.

Key finding:

  • Similar 1-year OS without QoL (SABR 55.2% vs chemo-SABR 53.3%).
  • SABR alone had toxicity and QoL impact.
  • Gr 3–4 tox: 8.8% (SABR alone) vs 60%.

Shankar Siva: OMET trial in oligometastatic HNSCC

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Authors: Juliette Thariat, et al.

Shankar Siva: OMET trial in oligometastatic HNSCC

Phase II randomized design:

  • 1–3 oligometastases, mostly lung.
  • Median OS ~42 mo both arms.
  • QoL deterioration (median drop):

– SABR: 16.7 patients.

– Chemo-SABR: 50 patients.

QoL assessed with EORTC QLQ-C30.”

Shankar Siva: OMET trial in oligometastatic HNSCC

Toxicity snapshot:

Grade ≥3 toxicity:

  • 60% with chemo vs 8.8% with SABR-only.
  • No grade 5 events.
  • Chemo toxicities: anemia, nausea, mucositis, hypomagnesemia, etc.

QoL declines closely linked to non-haem grade ≥3 toxicities.”

Bottom line for clinicians:

In select patients with oligometastatic HNSCC, SABR alone offers comparable survival with toxicity and better QoL.

Repeated SABR feasible at relapse SABR-only arm also shown to be cost-efficient.

Full paper.

Sue Yom–ASTRO upcoming podcast for APRIL 2025.”

anemia ASTRO cancer cetuximab chemotherapy EORTC fight against cancer Global fight against cancer GORTEC Head and Neck Cancer HNSCC hypomagnesemia Juliette Thariat mucositis nausea Oligometastases OMET OncoDaily Oncology Peter MacCallum Cancer Centre quality of life RadOnc SABR Shankar Siva Stereotactic Ablative Radiation Therapy Sue Yom
Special Coverage
Blog
Apr 20, 2025, 12:54
The invitation to the 6th Annual Meeting in Budapest is waiting for you - SIOP Europe
Blog
Apr 20, 2025, 12:40
Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC - LUNGevity Foundation
Science
Apr 20, 2025, 12:33
Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML
Blog
Apr 20, 2025, 12:23
Proud to have over 70 Cardio-Oncology Centers of Excellence around the world - International Cardio-Oncology Society
Blog
Apr 20, 2025, 12:18
Every child deserves a safe, welcoming space during cancer treatment - Childhood Cancer International
Blog
Apr 20, 2025, 12:15
Hidehito HORINOUCHI: Honored to have been nominated for IASLC 2025 Board of Directors Election
Societies
Apr 20, 2025, 12:10
Where to Study to Become ASCO President: 2025 Institutional Rankings
Blog
Apr 20, 2025, 12:03
NCODA - HealthWell Foundation has opened a fund to support individuals living with NETs
Blog
Apr 20, 2025, 12:02
Himil Mahadevia: Humbled to receive the 2025 Conquer Cancer Merit Award for our study on CART outcomes
Blog
Apr 20, 2025, 11:57
David Zaas: Inspiring day with the team at Atrium Health Wake Forest Baptist Wilkes Medical Center
Blog
Apr 20, 2025, 11:55
ESMO Fellowship applications are now open!
Blog
Apr 20, 2025, 11:55
Petros Grivas: Support to our fundraising effort for bladder cancer